PharmaCorp Enters Letter of Intent for the Acquisition of Pharmacy Files in Western Canada

SASKATOON, Saskatchewan, Dec. 11, 2025 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a non-binding letter of intent (“LOI”) to acquire from an arm’s length vendor (the “Vendor”) the prescription files, patient records, and related operational data (the “Pharmacy Files”) of a pharmacy located in the same community as one of PharmaCorp’s existing PharmaChoice-bannered pharmacies in Western Canada (the “Proposed Acquisition”). The purchase price for the Proposed Acquisition is anticipated to be $350,000 subject to customary adjustments. The Proposed Acquisition will be satisfied with cash on hand with closing expected to occur during the first quarter of 2026. No finder’s fees are payable in respect of the Proposed Acquisition.

The Proposed Acquisition does not involve the purchase of the target’s corporate entity, fixtures, or other operating assets. Following completion, all patient files are expected to be transferred to, and serviced by, PharmaCorp’s existing pharmacy in the community.

Completion of the Proposed Acquisition is subject to the execution of a definitive agreement which will include the final agreed upon terms and conditions of the Proposed Acquisition, including such terms, ‎representations, warranties, indemnities and covenants as ‎are customary in transactions similar to the ‎Proposed Acquisition, and the satisfaction of customary conditions, including satisfactory due diligence. There can be no assurance that the Proposed Acquisition will be completed as proposed, or at all.

“This transaction reflects our disciplined approach to growth and our commitment to strengthening patient care in the communities we serve,” said Alan Simpson, Executive Chair of the Board of PharmaCorp. “By integrating these Pharmacy Files into our existing pharmacy, we can enhance operational efficiency while ensuring continuity of care for local residents.”

PharmaCorp continues to advance its national consolidation strategy through disciplined acquisitions that enhance operational efficiency and long-term value for shareholders. The Corporation remains focused on integrating scalable opportunities, including pharmacy file acquisitions of this nature, that complement its existing pharmacy footprint.

About PharmaCorp Rx Inc.

PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners. Through a combination of capital, strategic support, and operational expertise, PharmaCorp is building a national network of community pharmacies under the PharmaChoice Canada banner. PharmaCorp currently operates seven PharmaChoice Canada bannered pharmacies and will continue to acquire both PharmaChoice Canada bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform in accordance with its strategic alliance with PharmaChoice Canada. PharmaCorp shares trade on the TSX Venture Exchange under the symbol: PCRX.

PharmaCorp actively welcomes discussions with pharmacy owners considering succession or sale. For more information about our acquisition program and process, please visit www.PharmaCorpRx.ca or contact our team confidentially. We are committed to seamless transitions that protect your legacy and serve your community.

For further information, please contact:

Investor Relations
info@pharmacorprx.ca
Tel: (306) 536-3771

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains “forward-looking information” regarding the Corporation within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the Proposed Acquisition including, the execution of a definitive agreement for the Proposed Acquisition, the potential closing and closing date of the Proposed Acquisition, the potential conditions and satisfaction of those conditions for the completion of the Proposed Acquisition, the consideration for the Proposed Acquisition, including the use of funds on hand, and the operational efficiencies created by the Proposed Acquisition; the Corporation’s focus on integrating scalable opportunities, including pharmacy file acquisitions similar to the Proposed Acquisition, that complement the Corporation’s existing pharmacy footprint; and the business of the Corporation, including the Corporation’s focus on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners and the Corporation’s goal of building a national network of community pharmacies under the PharmaChoice Canada banner and continuing to acquire both PharmaChoice Canada bannered and independent pharmacies across Canada. This forward-looking information reflects current beliefs and is based on information currently available to the management of the Corporation and on assumptions the Corporation believes are reasonable. These assumptions include, but are not limited to: satisfactory due diligence and the satisfaction of typical closing conditions in relation to the Proposed Acquisition; the receipt of all required approvals for the Proposed Acquisition‎, including any board approvals or third party consents; market acceptance of the Proposed Acquisition‎; the continued supply of pharmacies for purchase by the Corporation at prices satisfactory to Corporation; and the volume of acquisition opportunities presented to the Corporation being equal to or greater than historical volumes. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Corporation to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board of directors, third party or regulatory approvals; competition; changes in legislation, including pharmacy regulation, affecting the Corporation; the timing and availability of external financing on acceptable terms; conclusions of economic evaluations and appraisals; and lack of qualified, skilled labour or loss of key individuals. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Corporation’s disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although the Corporation has attempted to identify important risks and factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of the Corporation as of the date of this news release and, accordingly, is subject to change after such date. However, the Corporation expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.